Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study
European Journal of Neurology · 2024-07 · 31 (7)
DOI: 10.1111/ene.16292 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Neurology, online erschienen am 08.04.2024. Verfasst von Céline Tard und 22 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, University of Lille, Lille, France. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, alpha-Glucosidases, Enzyme Replacement Therapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amicus Therapeutics, Sanofi.
Abstract (Originalsprache)
Introduction
Late‐onset Pompe disease (LOPD) is characterized by a progressive myopathy resulting from a deficiency of acid α‐glucosidase enzyme activity. Enzyme replacement therapy has been shown to be effective, but long‐term treatment results vary. Avalglucosidase alfa demonstrated non‐inferiority to alglucosidase alfa in a phase 3 study, allowing in France compassionate access for advanced LOPD patients unresponsive to alglucosidase alfa.
Methods
Data from the French Pompe registry were analyzed for patients who benefited from a switch to avalglucosidase alfa with at least 1 year of follow‐up. Respiratory (forced vital capacity [FVC]) and motor functions (Six‐Minute Walk Test [6MWT]) were assessed before and 1 year after switching. Individual changes in FVC and 6MWT were expressed as slopes and statistical analyses were performed to compare values.
Results
Twenty‐nine patients were included (mean age 56 years, 11 years of prior treatment). The FVC and 6MWT values remained stable. The individual analyses showed a stabilization of motor worsening: –1 m/year on the 6MWT after the switch versus –63 m/year the year before the switch (i.e., a worsening of 33%/year before vs. an improvement of 3%/year later). Respiratory data were not statistically different.
Discussion
At the group level, gait parameters improved slightly with a stabilization of previous worsening, but respiratory parameters showed limited changes. At the individual level, results were discordant, with some patients with a good motor or respiratory response and some with further worsening.
Conclusion
Switching to avalglucosidase alfa demonstrated varied responses in advanced LOPD patients with failing alglucosidase alfa therapy, with a general improvement in motor stabilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, University of Lille, Lille, France.
- Centre de Référence des Maladies NeuroMusculaires Nord - Est - Ile-de-France, Filnemus, Garches, France.
- Centre de Référence des Maladies NeuroMusculaires PACA Réunion Rhône Alpes, Filnemus, Marseille, France.
- Service ENMG/Pathologies Neuromusculaires, Hospices Civils de Lyon, Lyon, France.
- Service de Neurologie, CHU de Nancy, Nancy, France.
- Service de Neurologie, CHRU Bretonneau, Tours, France.
ORCID-Profile: Céline Tard, Stephane Beltran, Emmeline Lagrange, Armelle Magot
Förderung
- Amicus Therapeutics
- Sanofi
Zitieren
APA
Tard, C., Bouhour, F., Michaud, M., Beltran, S., Fournier, M., Demurger, F., Lagrange, E., Nollet, S., Sacconi, S., Noury, J. B., Magot, A., Cintas, P., Renard, D., Deibener-Kaminsky, J., Lefeuvre, C., Davion, J. B., Salort-Campana, E., Arrassi, A., Taouagh, N., …, & Laforêt, P. (2024). Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study. European Journal of Neurology, 31(7). https://doi.org/10.1111/ene.16292
Vancouver
Tard C, Bouhour F, Michaud M, Beltran S, Fournier M, Demurger F, et al. Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study. European Journal of Neurology. 2024;31(7). doi:10.1111/ene.16292
BibTeX
@article{Tard2024,
author = {Tard, Céline and Bouhour, Françoise and Michaud, Maud and Beltran, Stephane and Fournier, Maxime and Demurger, Florence and Lagrange, Emmeline and Nollet, Sylvain and Sacconi, Sabrina and Noury, Jean-Baptiste and Magot, Armelle and Cintas, Pascal and Renard, Dimitri and Deibener-Kaminsky, Joëlle and Lefeuvre, Claire and Davion, Jean-Baptiste and Salort-Campana, Emmanuelle and Arrassi, Azzeddine and Taouagh, Nadjib and Spinazzi, Marco and Pompe Study Group, Pompe Study Group and Attarian, Shahram and Laforêt, Pascal},
title = {Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {7},
doi = {10.1111/ene.16292}
}
EUVIMED